Search results
Showing 676 to 690 of 2548 results for methods
Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]
In development Reference number: GID-TA11643 Expected publication date: 18 March 2026
In development Reference number: GID-TA11576 Expected publication date: 18 June 2026
In development Reference number: GID-TA11468 Expected publication date: 14 May 2026
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]
Awaiting development Reference number: GID-TA11018 Expected publication date: TBC
Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]
In development Reference number: GID-TA11553 Expected publication date: TBC
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]
In development Reference number: GID-TA10024 Expected publication date: 28 June 2017
In development Reference number: GID-TA11772 Expected publication date: 03 September 2026
Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)
This guideline covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. It does not cover managing severe asthma or acute asthma attacks.
Evidence-based recommendations on translaryngeal tracheostomy (TLT). This involves passing a tube from inside the windpipe to outside the neck to aid breathing.
This quality standard covers care for adults (aged 18 and over) who are malnourished or at risk of malnutrition in hospital or in the community. It includes identifying people at risk of malnutrition and providing nutrition support, including dietary changes and artificial nutrition support given through feeding tubes (enteral nutrition) or directly into a vein (parenteral nutrition). It describes high-quality care in priority areas for improvement.
View quality statements for QS24Show all sections
Sections for QS24
- Quality statements
- Quality statement 1: Screening for the risk of malnutrition
- Quality statement 2: Treatment
- Quality statement 3: Documentation and communication of results and nutrition support goals
- Quality statement 4: Self-management of artificial nutrition support
- Quality statement 5: Review
- About this quality standard
Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891]
In development Reference number: GID-TA11473 Expected publication date: TBC
In development Reference number: GID-TA11439 Expected publication date: TBC
L-Dex U400 for lymphoedema after breast cancer treatment (MIB111)
NICE has developed a medtech innovation briefing (MIB) on L-Dex U400 for lymphoedema after breast cancer treatment .
In development Reference number: GID-TA11508 Expected publication date: 29 July 2026
In development Reference number: GID-TA11599 Expected publication date: TBC